Singapore Parliament Q&A: Ensuring Sufficient Stock of Diabetes Medications

The Singapore Parliament discussed the issue of adequate stock of diabetes medications, particularly Ozempic and Wegovy, in response to rising demand driven by weight loss trends on social media. The Minister for Health addressed concerns regarding insufficient stocks and misuse of these medications for non-medical purposes. The Ministry works closely with healthcare institutions and drug companies to monitor usage patterns and ensure drug resiliency.

Key Takeaways:

The Minister for Health stated that Ozempic and Wegovy, containing Semaglutide, are Prescription Only Medicines (POM) registered in Singapore for treating diabetes and weight management in specific patient populations.
Doctors assess patients' conditions and prescribe these medications according to clinical guidelines, ensuring they are obtained through proper channels.
Social media trends marketing Ozempic and Wegovy as quick fixes for weight loss are misleading, and consumers should be aware of the associated risks of using these medications inappropriately.
The Ministry of Health (MOH) works closely with healthcare institutions and drug companies to monitor local and international usage patterns, minimizing potential disruption to treatment and ensuring drug resiliency.
The Ministry ensures that these medications are available for their prescribed medical use, and there are no plans to make them available for non-medical purposes.

Statistics:

Three GLP-1 agonists, including Ozempic and Wegovy, are registered as Prescription Only Medicines (POM) in Singapore to treat diabetes and weight management in specific patient populations.
MOH works closely with healthcare institutions (HCIs) and drug companies to monitor local and international usage patterns.

Sources:

May 9 -- Singapore Parliament Q&A: NOTICE PAPER NO. 1892 NOTICE OF QUESTION FOR WRITTEN ANSWER FOR THE SITTING OF PARLIAMENT ON 8 MAY 2023, Source: Ministry of Health (MOH), Government of Singapore